About Apconix
ApconiX: Pioneering Nonclinical Toxicology and Safety Science
ApconiX is a leading integrated toxicology and ion channel company that has been at the forefront of innovative thinking in nonclinical toxicology and safety science. The company was founded by Dr. Michael Morton, Dr. Richard Knight, and Professor Ruth Roberts in 2015 with the aim of providing expert advice to pharmaceutical, biotech, and chemical companies on drug safety issues.
The team at ApconiX comprises highly experienced scientists who have worked in both industry and academia. They have a deep understanding of the regulatory requirements for drug development and are committed to helping their clients navigate the complex landscape of nonclinical safety testing.
One of ApconiX's key strengths is its expertise in ion channels - proteins that play a crucial role in many physiological processes such as muscle contraction, nerve signaling, and hormone secretion. Ion channels are also important targets for drugs used to treat a wide range of diseases including epilepsy, hypertension, pain, and cancer.
ApconiX's scientists have extensive experience in studying ion channels using electrophysiology - a technique that measures the electrical activity generated by these proteins. This expertise allows them to provide valuable insights into how drugs interact with ion channels and how this can impact their safety profile.
In addition to its work on ion channels, ApconiX offers a range of other services related to nonclinical toxicology including:
- Safety assessment: evaluating the potential toxicity of new drugs or chemicals using state-of-the-art techniques such as high-throughput screening assays.
- Risk assessment: assessing the risks associated with exposure to chemicals or environmental pollutants.
- Regulatory support: providing expert advice on regulatory requirements for drug development including FDA/EMA guidelines.
ApconiX's approach is based on collaboration with its clients - working closely with them throughout all stages of drug development from discovery through clinical trials to market approval. This ensures that potential safety issues are identified early on and can be addressed before they become a major problem.
The company's commitment to quality is reflected in its ISO 9001:2015 certification - an internationally recognized standard for quality management systems. This ensures that all of ApconiX's services are delivered to the highest standards of quality and reliability.
In summary, ApconiX is a pioneering company that is leading the way in nonclinical toxicology and safety science. Its team of expert scientists has extensive experience in ion channel research and provides valuable insights into drug safety issues. With its commitment to collaboration, quality, and regulatory compliance, ApconiX is an ideal partner for pharmaceutical, biotech, and chemical companies looking to develop safe and effective drugs.